Innovations can help India's biotech economy hit $100 bn by 2025: Kant

"India's biotechnology economy can approach $100 billion in 2025 if the right policies are put in place, giving industry the required stimulation," he said

NITI, niti, niti aayog, Amitabh Kant
CEO of NITI Aayog Amitabh Kant
Press Trust of India New Delhi
1 min read Last Updated : Jul 24 2020 | 11:41 PM IST
The Indian biotechnology space has potential to grow to $100 billion in size by 2025 on the back of innovations in bio-manufacturing technologies, Niti Aayog CEO Amitabh Kant said on Friday.

Addressing a webinar titled 'Global Perspective on India's Biotech Potential: Manufacturing Hub & Foreign Investment', Kant said India is working to boost the biotechnology sector under the flagship programmes like 'Make in India' and 'Startup India'.

"India's biotechnology economy can approach $100 billion in 2025 if the right policies are put in place, giving industry the required stimulation," he said.

Kant said India has established biotechnology parks and incubators across the country to facilitate scientists and MSMEs with technology demonstration, along with pilot studies for accelerated commercial development.

Noting that an increase in the number of biotech incubators can boost research and promote the growth of startups, Kant said, "Innovations in bio-manufacturing technologies are critical for the success of the Indian biotech industry.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :BiotechnologyAmitabh KantIndian Economy

Next Story